Profibrotic effect of IL-9 overexpression in a model of airway remodeling.
IL-9 overexpression protects against alveolar fibrosis induced by crystalline silica particles. This cytokine is also involved in allergic asthma. In the present study, we examined the effect of IL-9 overexpression on the subepithelial fibrotic response, a feature of asthmatic remodeling, induced by chronic exposure to Alternaria alternata extract. IL-9-overexpressing mice (Tg5) and their wild-type counterparts (FVB) were intranasally exposed to A. alternata extract or PBS (controls) twice a week during 3 mo. At the end of the allergic challenge, enhanced pause (Penh) measured in response to methacholine and fibrotic parameters, such as collagen and fibronectin lung content, were significantly higher in Tg5 compared with FVB. Staining of lung sections with Masson's Trichrome also showed more collagen fibers in peribronchial areas of treated Tg5 mice. A similar recruitment of inflammatory cells was observed in challenged FVB and Tg5 mice, except for eosinophils, which were significantly more abundant in the lung of Tg5. High serum levels of IgE and IgG1 in both strains indicated that FVB and Tg5 developed a strong type 2 immune response. The concentration of the eosinophil chemoattractant RANTES and the profibrotic mediator connective tissue growth factor (CTGF) was higher in the BAL of challenged Tg5 than FVB. These results demonstrate a profibrotic role of IL-9 in an airway remodeling model, possibly involving eosinophils and CTGF. These data also highlight a dual role of IL-9 in lung fibrosis, being anti- or profibrotic depending on the alveolar or airway localization of the process, respectively.
van den Brûle
Sybille
S
Unit of Industrial Toxicology and Occupational Medicine, Université catholique de Louvain, Avenue Mounier, 53.02, 1200 Brussels, Belgium. Sybille.vandenBrule@uclouvain.be
Heymans
Julie
J
Havaux
Xavier
X
Renauld
Jean-Christophe
JC
Lison
Dominique
D
Huaux
François
F
Denis
Olivier
O
D000528:Alternaria / Q000276:immunology; D000818:Animals; D001249:Asthma / Q000276:immunology / Q000473:pathology; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D018946:Chemokine CCL5 / Q000378:metabolism; D003094:Collagen / Q000378:metabolism; D055513:Connective Tissue Growth Factor; D004195:Disease Models, Animal; D004804:Eosinophils / Q000166:cytology / Q000276:immunology; D005260:Female; D005355:Fibrosis / Q000276:immunology* / Q000473:pathology; D006801:Humans; D017874:Immediate-Early Proteins / Q000378:metabolism; D007073:Immunoglobulin E / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism; D016906:Interleukin-9 / Q000235:genetics / Q000276:immunology*; D008168:Lung / Q000473:pathology / Q000502:physiology; D051379:Mice; D008822:Mice, Transgenic
C526317:CCN2 protein, human; C526318:CCN2 protein, mouse; D018946:Chemokine CCL5; D017874:Immediate-Early Proteins; D007074:Immunoglobulin G; D036341:Intercellular Signaling Peptides and Proteins; D016906:Interleukin-9; D055513:Connective Tissue Growth Factor; D007073:Immunoglobulin E; D003094:Collagen